<DOC>
	<DOCNO>NCT02855086</DOCNO>
	<brief_summary>This pilot phase I/II trial study best dose cetuximab-IRDye 800CW well work detect tumor patient malignant glioma undergo surgery . Cetuximab-IRDye 800CW optical image agent may help detect tumor cell special camera use .</brief_summary>
	<brief_title>Cetuximab-IRDye 800CW Detecting Tumors Patients With Malignant Glioma Undergoing Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine efficacy cetuximab-IRDye 800CW ( cetuximab IRDye800 ) intraoperatively identify malignant glioma compare surround normal central nervous system tissue , measure tumor-to-background ratio . SECONDARY OBJECTIVES : I . To determine tolerability cetuximab IRDye800 imaging agent subject undergoing resection malignant glioma . OUTLINE : This dose-escalation study cetuximab-IRDye 800CW . Patients assign 1 2 cohort . COHORT I : Patients receive cetuximab intravenously ( IV ) 30 minute low dose cetuximab IRDye800 IV 30 minute 1 hour day 0 . COHORT II : Patients receive cetuximab IV 30 minute higher dose cetuximab IRDye800 IV 30 minute 1 hour day 0 . All patient undergo standard care surgical resection tumor day 2-5 . After completion study , patient follow day 10 30 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects suspect brain tumor undergoing surgical removal standard care eligible ; may include subject status post chemotherapy and/or radiation subject undergone diagnostic biopsy original diagnosis felt candidate resection Subjects must eligible resection determine operate surgeon Planned standard care surgery Life expectancy 12 week Karnofsky performance status least 70 % Eastern Cooperative Oncology Group ( ECOG ) /Zubrod level 1 Hemoglobin &gt; = 9 gm/dL Platelet count &gt; = 100,000/mm^3 Magnesium , potassium calcium &gt; low limit normal per institution normal lab value Thyroidstimulating hormone ( TSH ) &lt; 13 micro international units/mL Received investigational drug within 30 day prior first dose cetuximab IRDye800 Myocardial infarction ( MI ) ; cerebrovascular accident ( CVA ) ; uncontrolled congestive heart failure ( CHF ) ; significant liver disease ; unstable angina within 6 month prior enrollment History infusion reaction cetuximab monoclonal antibody therapy Pregnant breastfeed Subjects serious reaction test/loading cetuximab dose able receive full dose Evidence QT prolongation pretreatment electrocardiogram ( ECG ) ( great 440 m male great 450 m female ) Lab value opinion primary surgeon would prevent surgical resection Subjects receive class IA ( quinidine , procainamide ) class III ( dofetilide , amiodarone , sotalol ) antiarrhythmic agent Subjects deemed appropriate candidate optimal resection tumor base location , involvement eloquent brain , satellite lesion , factor specifically list</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>